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A utoimmune polyglandular syndrome (APS) is defined as multiple endocrine gland disorders 
[1].  APS is categorized as types 1 to 4.  Among them,  
only type 3 APS is not accompanied by Addison’s dis-
ease,  but type 3 APS includes several autoimmune dis-
eases such as type 1 diabetes,  autoimmune thyroid dis-
ease,  and collagen disease [1-3].  Here we describe the 
case of a 61-year-old woman who newly developed 
systemic lupus erythematosus (SLE) 8 years after the 
first diagnosis of autoimmune hepatitis (AIH),  slowly 
progressive insulin-dependent diabetes mellitus 
(SPIDDM),  and chronic thyroiditis.
Case Presentation
A 53-year-old Japanese woman was referred to our 
hospital because of her high serum concentrations of 
AST (327 U/L) and ALT (541 U/L).  A detailed exam-
ination had revealed antinuclear antibody positivity 
(× 160 with homogenous pattern and × 1,260 with 
nucleolar pattern),  elevated IgG (3,007 mg/dL),  and 
negative viral serology: HBsAg (−),  HBsAb (−) and 
HCV (−).  Her liver biopsy demonstrated interface hep-
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Eight years prior to her present admission,  a 61-year-old Japanese woman was diagnosed with autoimmune 
hepatitis,  slowly progressive insulin-dependent diabetes mellitus,  and chronic thyroiditis; she had been treated 
with oral prednisolone (PSL).  After she suddenly discontinued PSL,  she newly developed systemic lupus ery-
thematosus.  A combination therapy of oral PSL and intravenous cyclophosphamide resulted in remission.  She 
was finally diagnosed with autoimmune polyglandular syndrome (APS) type 3 (3A , 3B , 3D),  complicated with 
four different autoimmune diseases.  Since patients with type 3 APS may present many manifestations over a 
long period of time,  they should be carefully monitored.
Key words:  autoimmune polyglandular syndrome type 3,  systemic lupus erythematosus,  autoimmune hepatitis,  
slowly progressive insulin-dependent diabetes mellitus,  chronic thyroiditis
Received October 12, 2018 ; accepted March 22, 2019.
＊Corresponding author. Phone : +81-86-235-7235; Fax : +81-86-222-5214
E-mail : hauchida@okayama-u.ac.jp (HA. Uchida)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
atitis with a lymphoplasmacytic infiltration of portal 
tracts and focal necrosis (Fig. 1A-C).  At this point,  
anti-Sm antibody was negative (< 5.0 index) and com-
plement levels were in normal ranges (C3 113.7 mg/dL,  
C4 14.9 mg/dL,  CH50 41 U/mL).  Antinuclear anti-
body,  anti-dsDNA antibody,  and anti-cardiolipin anti-
body were not measured.
Based on these findings,  we diagnosed AIH and 
initiated oral prednisolone (PSL) 20 mg/day.  After the 
initiation of PSL therapy,  she presented postprandial 
hyperglycemia; her blood glucose level was >300 mg/dL,  
without ketosis or ketoacidosis.  We administered an 
additional examination which revealed that the patient’s 
fasting glucose level was 85 mg/dL,  HbA1c was 5.6%,  
and insulin secretion was maintained (urine C-peptide 
141.0 µg/day),  while glutamic acid decarboxylase auto-
antibody (GADAb) was positive (20.6 U/mL).  The 
evaluation of hormonal values showed a thyroid-stimu-
lating hormone (TSH) elevation with low free T4 and 
free T3 levels,  and positivity to antibodies against thy-
roid peroxidase (TPOAb),  thyroglobulin (TgAb),  and 
TSH receptor (TRAb).
Given these findings,  we diagnosed SPIDDM and 
chronic thyroiditis.  The PSL was gradually tapered to 
2.5 mg/day over 5 years.  Strict diet and exercise ther-
apy managed her HbA1c level at < 6.0%.  Low-dose PSL 
(2.5 mg/day) was continued for 3 years.  However,  the 
patient suddenly discontinued her medication by her 
own decision,  and 1 month later,  she presented with a 
rash on her face,  edema of her legs and face,  stomatitis,  
and fever.  She was thus admitted to our hospital in 
2017.
On physical examination,  she was ill-appearing 
and febrile at 38.5°C.  Her blood pressure was 
115/87 mmHg,  and her pulse rate was 107/min,  with 
O2 saturation of 98% on room air.  She had small rushes 
on her face and edema of her legs and face.  Struma was 
not palpable.  She had no history of vitiligo or alopecia.  
The results of a cardiovascular examination were nor-
mal; the lungs were clear to auscultation,  and an 
abdominal examination was unremarkable.
The patient’s laboratory data are summarized in 
Table 1.  Liver enzymes were elevated without hepatitis 
viral infection or IgG elevation.  Serum levels of FT3 
and FT4 were low.  The serum levels of adrenocortico-
tropic hormone (ACTH),  luteinizing hormone (LH),  
follicle-stimulating hormone (FSH),  growth hormone 
(GH) and prolactin (PRL) were all within the normal 
ranges.  TPOAb,  TgAb,  and TRAb were seropositive.  
HbA1c was 8.1%,  GADAb was elevated to 1,586.5 U/mL,  
and insulin secretion was severely depleted (urine 
C-peptide 3.8 µg/day),  suggesting an insulin-depen-
dent status.  Other laboratory investigations showed 
leukopenia,  anemia,  and kidney injury.  A urine analy-
sis showed protein (2 + ),  751.1 mg/day,  but occult 
blood was negative.  Antinuclear antibody,  anti-dsDNA 
antibody,  anti-Sm antibody and anti-cardiolipin anti-
body were seropositive,  and she had hypocomplemen-
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Fig. 1　 Histological ﬁndings of the patientʼs 
liver biopsy.  A,  Accumulation of inﬂammatory 
cells in portal tract.  Hematoxylin and eosin 
(H&E) stain; B,  The limiting plate of the portal 
tract is disrupted by a lymphoplasmacytic inﬁltra-
tion.  H&E stain; C,  Many inﬂammatory cells in 
liver parenchyma.  H&E stain.
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Table 1　 Laboratory data on admission
【Urinalysis】 AST 64 U/L LAC 1.0 mL/min/1.73m2
pH 6.0 ALT 35 U/L anti-CL.β2GPI Ab 2.1 U/mL
Pro (2+ ) ALP 158 U/L anti-M2 Ab -
Glu (－) γ-GTP 35 U/L
Bld (－) LDH 370 U/L 【Endocrinology】
Ket (－) Na 129 mEq/L freeT3 1.52 pg/mL
Bil (－) K 4.1 mEq/L freeT4 0.64 ng/dL
NAG 4.7 U/L Cl 101 mEq/L TSH 0.35 µU/mL
β2MG 1.660 µg/mL Ca 7.3 mg/dL TGAb 30.1 IU/mL
u-TP 0.75 g/day IP 2.2 mg/dL TPOAb 72.9 IU/mL
UN 22.2 mg/dL TRAb 3.40 IU/L
【Complete blood count】 Cr 1.02 mg/dL ACTH 10.0 pg/mL
WBC 3,220 /µL UA 7.4 mg/dL FSH 76.5 mIU/mL
 Sg 52.0 % CRP 0.12 mg/dL LH 24.6 mIU/mL
 St 13.0 % Ferritin 1,779.0 ng/mL GH 1.59 ng/mL
 Lymph 24.0 % Hpt 149 mg/dL PRL 15.1 ng/mL
 Mono 10.0 % AVP 1.7 pg/mL
 Eosi 0.0 % 【Serological data】 Cor 12.3 µg/dL
 Baso 0.0 % C3 21.1 mg/dL
RBC 354×104 /µL C4 2.1 mg/dL 【Diabetology】
Hb 10.8 g/dL CH50 <14 U/mL HbA1c (NGSP) 8.1 %
Ht 31.0 % IgG 1,397.9 mg/dL glucose 120 mg/dL
Plt 18.5×104 /µL IgA 500.3 mg/dL C-peptide 1.95 ng/mL
IgM 38.2 mg/dL IRI 6.2 µU/mL
【Coagulation test】 PR3-ANCA <0.50 IU/mL GAD Ab 1,586.5 U/mL
PT 11.7 sec MPO-ANCA <0.50 IU/mL ZnT8 Ab <10.0 U/mL
PT-INR 1.10 anti-GBM Ab 1.78 IU/mL u-CPR 3.8 µg/day
APTT 34.1 sec RF <5.0 IU/mL
D-D 17.6 µg/mL anti-nuclear Ab ×640 (HOMOGE) 【Infections】
anti-SM Ab 16.5 U/mL HBsAb -
【Biochemistry】 anti-dsDNA Ab 211.00 IU/mL HbsAg -
TP 5.7 g/dL anti-SS-A Ab 31.90 U/mL HCVAb -
Alb 2.6 g/dL anti-SS-B Ab 0.82 U/mL
T-Bil 0.49 mg/dL anti-cardiolipin Ab 22.90 U/mL
NAG,  N-acetyl-β-D-glucosaminidase; β2MG,  β2microglibulin; u-TP,  urinary-total protein; WBC,  white blood cell; Sg,  segmented 
cell; St,  stab cell; Lymph,  lymphocyte; Mono,  monocyte; Eosi,  eosinophil; Baso,  basophil; RBC,  red blood cell; Hb,  hemoglobin; Ht,  
hematocrit; Plt,  platelet; PT,  prothrombin time; PT-INR,  prothrombin time-international normalized ratio; APTT,  activated partial throm-
boplastin time; D-D,  D-dimer; TP,  total protein; Alb,  albumin; T-Bil,  total-bilirubin; AST,  aspartate aminotransferase; ALT,  alanine 
aminotransferase; ALP,  alkaline phosphatase; γ-GTP,  γ-glutamyl transpeptidase; LDH,  lactate dehydrogenase; Na,  sodium; K,  potas-
sium; Cl,  chloride ; Ca,  calcium; IP,  inorganic phosphate; UN,  urea nitrogen; Cr,  creatinine; UA,  uric acid; CRP,  cross-reactive pro-
tein; Hpt,  haptoglobin; C3,  complement C3; C4,  complement C4; CH50,  hemolytic complement; IgG,  immunoglobulin G; IgA,  immu-
noglobulin A; IgM,  immunoglobulin M; PR3-ANCA,  proteinase 3-anti-neutrophil cytoplasmic antibody; MPO-ANCA,  myeloperoxidase 
anti-neutrophil cytoplasmic antibody; anti-GBM Ab,  anti-glomerular basement membrane antibody; RF,  rheumatoid factor; anti-nuclear Ab,  
anti-nuclear antibody; anti-SM Ab,  anti-smith antibody; anti-dsDNA Ab,  anti-double stranded DNA antibody; LAC,  lupus anticoagu-
lant; anti-CL.β2GPI Ab,  anti-cardiolipin.β2-glycoproteinI Ab; anti-M2,  antibody anti-mitochondrial M2 Ab; freeT3,  free triiodothy-
ronine; freeT4,  free thyroxine; TSH,  thyroid stimulating hormone; TGAb,  thyroglobulin antibody; TPOAb,  thyroid peroxidase anti-
body; TRAb,  TSH receptor autoantibody; ACTH,  adrenocorticotropic hormone; FSH. follicle stimulating hormone; LH,  luteinizing 
hormone; GH,  growth hormone; PRL,  prolactin; AVP,  arginine vasopressin; Cor,  cortisol; HbA1c,  Hemoglobin A1c; IRI,  immunoreac-
tive insulin; GAD Ab,  glutamic acid decarboxylase antibody; ZnT8 Ab,  zinc transporter 8 antibody; u-CPR,  urinary-C-peptide immunore-
activity; HBsAb,  Hepatitis B surface antibody; HbsAg,  Hepatitis B surface antigen; HCVAb,  Hepatitis C virus antibody
temia.  A human leukocyte antigen (HLA) analysis 
showed positive A24,  A26,  B54,  B59,  DRB1 04:05:01,  
and DQB1 04:01:01.
Computed tomography (CT) revealed ground glass 
opacity in the superior lobe of the right lung,  bilateral 
pleural effusion,  pericardial effusion,  and ascites.  The 
results of an ultrasound examination of thyroid were 
consistent with chronic thyroiditis.  A kidney biopsy 
revealed diffuse lupus nephritis class IV-G(A) with wire 
loop lesion,  hyaline thrombus,  and endo-capillary pro-
liferation (Fig. 2A-C).  Additional staining for anti-
GAD antibody,  anti-IA-2 antibody,  and anti-Thyro-
globulin antibody was performed.  All antibodies 
showed positive staining (Fig. 2D).
In light of these data,  we concluded that the patient 
was suffering from SLE in association with AIH,  
SPIDDM,  and chronic thyroiditis.  We thus diagnosed 
type 3 (3A , 3B, 3D) APS.  We immediately adminis-
tered PSL at 40 mg/day (1.0 mg/kg/day) and intrave-
nous cyclophosphamide (500 mg/month).  After the 
initiation of this therapy,  the patient’s physical status 
and laboratory data improved notably (Fig. 3).  On the 
47th hospital day,  she was discharged.  At present,  she 
is taking PSL 10 mg/day and levothyroxine sodium 
25 μg/day,  with insulin therapy.
Discussion
This was a rare case of type 3 APS,  complicated with 
four different autoimmune diseases,  i.e.,  AIH,  
SPIDDM,  chronic thyroiditis,  and SLE.  APS is charac-
terized by the coexistence of at least 2 autoimmune 










Fig. 2　 Kidney biopsy.  A,  Immunoﬂuorescence staining.  The full-house pattern with intense or diﬀuse staining in the glomerular 
mesangial lesion and capillary loops of all three immunoglobulins and complements (C3 and C1q) and ﬁbrinogen are observed; B,  Light 
microscopy ﬁndings.  Diﬀuse proliferative global glomerulonephritis with the following ﬁndings are observed; glomerular sub-endothelial 
deposits with wire loops lesion,  endo-capillary proliferation,  hyaline thrombus in almost all glomeruli,  and double counter of base mem-
brane in some glomeruli.  No crescent formation is observed.  Interstitial inﬂammation is mild; C,  Electron microscopy ﬁndings.  Diﬀuse and 
massive sub-endothelial dense deposits,  mild endo-capillary proliferation,  and frequent mesangial interposition are seen.  No sub-epithelial 
and intramembranous deposits are observed.  Eﬀacement of foot processes is observed in part; D,  Immunoﬂuorescence staining for anti-
GAD antibody,  anti-IA-2 antibody,  and anti-thyroglobulin antibody.  All antibodies showed positive staining granularly and focally in glomer-
ular capillary and mesangial lesions.
endocrine gland insufficiencies,  and non-endocrine 
autoimmune diseases may occur.  APS is categorized 
into four types based on the patient’s age at presenta-
tion,  the combination of diseases,  and genetics.  Type 1 
APS usually occurs in childhood.  It is defined by 
chronic mucocutaneous candidiasis,  acquired hypo-
parathyroidism,  and adrenal failure (Addison’s disease).  
It is caused by mutations in the AIRE gene on chromo-
some 21 and is inherited in an autosomal recessive 
manner.  Mutations in the AIRE gene disturb the body’s 
immunological tolerance.
Types 2,  3,  and 4 APS occur in adulthood.  Only 
type 3 APS does not involve adrenal failure.  Type 1 
diabetes,  Graves’ disease,  Hashimoto thyroiditis,  vitil-
igo,  alopecia,  hypogonadism,  pernicious anemia,  and 
collagen diseases are frequent complications of these 
types of APS,  and the manifestations of these pheno-
types usually do not occur simultaneously.  Unlike type 
1 APS,  types 2-4 are associated with many factors such 
as HLA,  polygenic polymorphism,  and environmental 
factors.  HLA DR3,  DR4,  DQA1 0301 and 0501,  and 
DR3-DQB1 0201 are correlated with APS type 2 [4, 5],  
and DR3-DQ2,  DRB1 0401-DQ8,  and DRB1 
0405, 0802 are correlated with APS type 3 [6].  PTPN22 
(protein tyrosine phosphatase non-receptor type 22),  
MICA (MHC class I polypeptide-related sequence A),  
CTLA-4 (cytotoxic T lymphocyte-associated antigen 4),  
and FOXP3 (forkhead boxP3) genes are known to be 
susceptibility gene variants that may lead to the loss of 
immunological tolerance [7 , 8].  Our patient had HLA 
DRB1 04:05,  which is related to type 3 APS.
In addition to such a genetic background in our 
patient,  her sudden cessation of PSL might have caused 
a failure of immunological tolerance,  followed by re-ac-
tivation of the inflammatory status and the excessive 
production of various autoantibodies.
Regarding the onset of various manifestations of 
APS,  there appears to be no fixed pattern [9-12]: some 
patients first present type 1 diabetes and/or autoim-
mune thyroid disease,  then suffer from SLE at 1 year or 
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Fig. 3　 Clinical course.  After diagnosis based on the kidney biopsy results,  the patient was administered PSL 40 mg/day (1.0 mg/kg/
day).  She was also given monthly intravenous cyclophosphamide for 6 months,  followed by maintenance therapy with PSL alone.  The 
proteinuria disappeared,  the level of liver enzymes and complements improved within normal ranges,  and anti-dsDNA antibody was gradu-
ally decreased.  IVCY: intravenous cyclophosphamide.
a few years later,  whereas others present type 1 diabetes 
or autoimmune thyroid disease with SLE simultane-
ously.  These reports support the possibility that the 
manifestation of SLE in patients with type 3 APS occurs 
due not only to the patients’ genetic background but 
also environmental factors.  Our patient developed SLE 
at 8 years after she had been diagnosed with 3 autoim-
mune diseases.  In her case,  the sudden cessation of PSL 
might have been the trigger for the development of SLE 
as an environmental factor.
In our patient,  the immunohistochemistry analyses 
showed the deposition of immune complex of various 
autoantibodies in the patient’s kidney tissue,  suggesting 
that these autoantibodies themselves or immune com-
plexes,  at least including these autoantibodies,  are 
associated with the development of lupus nephritis.  
This might be one of the reasons why temporal and spa-
tial diversity occurs in various manifestations of type 3 
APS.
Regarding the treatment of patients with type 3 APS,  
each of their diseases should be managed properly.  In 
our patient’s case,  SLE with diffuse lupus nephritis class 
IV-G(A) was diagnosed.  Lupus nephritis class IV-G is 
currently the most prevalent form in Japan and is asso-
ciated with a more severe clinical renal presentation 
[13].  The clinical outcome of lupus nephritis class IV-G 
for end-stage renal disease is very poor [14],  thus 
necessitating intensive treatment including methyl-
prednisolone pulse therapy.  In our patient’s case,  the 
combination therapy of oral PSL and IVCY successfully 
resulted in remission as well as normal levels of liver 
enzymes.  Since our patient is relatively old,  careful and 
continuous monitoring will be needed to avoid infec-
tion by immunosuppressive treatment.  Her diabetic 
status was well-controlled by insulin therapy with a 
proper diet regimen.  Her thyroid function was con-
trolled within the normal range by the proper dosage of 
levothyroxine sodium,  although the pathophysiological 
meaning of TRAb seropositive is obscure.  No other 
specific treatment is required.
Since patients with type 3 APS may present many 
manifestations over a long period of time,  these com-
plications should be taken into consideration even when 
the patients received treatment.
Final diagnosis. Autoimmune polyglandular 
syndrome type 3 associated with systemic lupus erythe-
matosus.
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